A study on the utilization of canagliflozin in type 1 diabetes mellitus using real‐world data from four European countries
Authors' conclusion
Real-world data analyses from four European countries showed that off-label use of canagliflozin for T1DM was rare.
Study context
- Population
- Canagliflozin users with T1D in Belgium, Italy, Spain and UK, 2016–2022
- Outcome
- Prevalence and incidence of off-label canagliflozin use in T1D
- Follow-up
- 2016–2022, overall and by year
Methodological detailsobservational, real-world data, 4 European countries, 6 healthcare databases
- Observational
- Real-world data
- 4 European countries
- 6 healthcare databases
Main finding
As reported in the abstract
2016–2022
Overall prevalence and incidence consistently low across 6 databases (primary and sensitivity T1D definitions)
0.0% to 0.2%
Observational data: associations, not effects.
Further findings
Trend in new canagliflozin users with T1D over time · by year
- Trend analysis not feasible; annual prevalence and incidence censored for many years
Safety
Diabetic ketoacidosis (DKA) among canagliflozin users with T1D
- Few (number censored) to no DKA events in each database
Original publication
A study on the utilization of canagliflozin in type 1 diabetes mellitus using real‐world data from four European countries. Diabetes Obes Metab. Published 2 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →